Clinical significance of 18F-α-methyl tyrosine PET/CT for the detection of bone marrow invasion in patients with oral squamous cell carcinoma: Comparison with 18F-FDG PET/CT and MRI

Annals of Nuclear Medicine

Volumn 27, Issue 5, 2013, Pages 423-430

  Kim, Mai ^a   Higuchi, Tetsuya ^a   Arisaka, Yukiko ^a   Achmad, Arifudin ^a   Tokue, Azusa ^a   Tominaga, Hideyuki ^a   Miyashita, Go ^a   Miyazaki, Hidetaka ^a   Negishi, Akihide ^a   Yokoo, Satoshi ^a   Tsushima, Yoshito ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

18F FDG; L 3 18F fluoro methyl tyrosine (18F FAMT); MRI; Oral squamous cell carcinoma (OSCC); PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METIROSINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2 FLUORO ALPHA METHYLTYROSINE; 2-FLUORO-ALPHA-METHYLTYROSINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; TYROSINE;

ADULT; AGED; ALVEOLAR RIDGE; ARTICLE; BONE MARROW; BONE METASTASIS; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MOUTH SQUAMOUS CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PET SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; BONE MARROW CANCER; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; REPRODUCIBILITY; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE MARROW NEOPLASMS; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOUTH NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TYROSINE;

EID: 84879008541     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0701-0     Document Type: Article

References (26)

1. Cancer Research UK, International Agency for Research on Cancer. Cancer Stats: Cancer Worldwide. 2011.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
3. Cooper JS, Porter K, Mallin K, Hoffman HT, Weber RS, Ang KK, et al. National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck. 2009;31(6):748-58.
4. Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, et al. Head and neck cancers. J Natl Compr Canc Netw. 2011;9(6):596-650.
5. 18F-Fluorodeoxyglucose-PET/CT to evaluate tumor, nodal disease, and gross tumor volume of oropharyngeal and oral cavity cancer: comparison with MR imaging and validation with surgical specimen. Neuroradiology. 2009;51(10):677-86.
6. Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Canc Res. 2007;13(21):6369-78.
7. Isoda A, Higuchi T, Nakano S, Arisaka Y, Kaira K, Kamio T, et al. (18)F-FAMT in patients with multiple myeloma: clinical utility compared to (18)F-FDG. Ann Nucl Med. 2012;26(10):811-6.
8. 18F]fluoroethyl-L-tryptophan as a novel potential amino acid PET tracer. Appl Radiat Isot. 2012;70(4):676-80.
9. Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, et al. Detection of malignant tumors: whole-body PET with fluorine 18 α-methyl tyrosine versus FDG-preliminary study. Radiology. 2001;220(1):54-62.
10. 18F-α-methyltyrosine using a separation and purification system. Nucl Med Commun. 1997;18:169-75.
11. Inoue T, Tomiyoshi K, Higuchi T, Ahmed K, Sarwar M, Aoyagi K, et al. Biodistribution studies on L-3-[Fluorine-18] fluoro-α-methyl tyrosine: a potential tumor detecting agent. J Nucl Med. 1998;39:663-7.
12. 18F α-methyl Tyrosine PET studies in patients with brain tumors. J Nucl Med. 1999;40:399-405.
13. Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, et al. Transport of 3-fluoro-L-alpha-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med. 2012;53(8):1253-61.
14. Ord RA, Sarmadi M, Papadimitrou J. A comparison of segmental and marginal bony resection for oral squamous cell carcinoma involving the mandible. J Oral Maxillofac Surg. 1997;55(5):470-7. discussion 7-8.
15. Wax MK, Bascom DA, Myers LL. Marginal mandibulectomy vs segmental mandibulectomy: indications and controversies. Arch Otolaryngol Head Neck Surg. 2002;128(5):600-3.
16. Rajesh A, Khan A, Kendall C, Hayter J, Cherryman G. Can magnetic resonance imaging replace single photon computed tomography and computed tomography in detecting bony invasion in patients with oral squamous cell carcinoma? Br J Oral Maxillofac Surg 2008;46(1):11-4. doi: 10.1016/j.bjoms.2007. 08.024.
17. 18F alpha-methyl tyrosine positron-emission tomography. Neuroradiology. 2003;45(10):700-7. doi: 10.1007/s00234-003-1057-2.
18. Abd El-Hafez YG, Chen CC, Ng SH, Lin CY, Wang HM, Chan SC, et al. Comparison of PET/CT and MRI for the detection of bone marrow invasion in patients with squamous cell carcinoma of the oral cavity. Oral Oncol. 2011;47(4):288-95. doi: 10.1016/j.oraloncology.2011.02.010.
19. Moule RN, Kayani I, Prior T, Lemon C, Goodchild K, Sanghera B, et al. Adaptive 18fluoro-2-deoxyglucose positron emission tomography/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer. Clin Oncol (R Coll Radiol). 2011;23(5):364-71. doi: 10.1016/j.clon.2010.11.001.
20. 18f]-fluoro-alpha- methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med. 2007;21(2):129-35.
21. Imaizumi A, Yoshino N, Yamada I, Nagumo K, Amagasa T, Omura K, et al. A potential pitfall of MR imaging for assessing mandibular invasion of squamous cell carcinoma in the oral cavity. AJNR Am J Neuroradiol. 2006;27(1):114-22.
22. van den Brekel MW, Runne RW, Smeele LE, Tiwari RM, Snow GB, Castelijns JA. Assessment of tumour invasion into the mandible: the value of different imaging techniques. Eur Radiol. 1998;8(9):1552-7.
23. Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006;104(2):238-53. doi: 10.3171/jns.2006.104.2.238.
24. Hong R, Halama J, Bova D, Sethi A, Emami B. Correlation of PET standard uptake value and CT window-level threshold for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys. 2007;67(3):720-6. doi: 10.1016/j.ijrobp.2006.09.039.
25. Wong RJ. Current status of FDG-PET for head and neck cancer. J Surg Oncol. 2008;97:649-52.
26. Xu G, Li J, Zuo X, Li C. Comparison of whole body positron emission tomography (PET)/PET-computed tomography and conventional anatomic imaging for detecting malignancies in patients with head and neck cancer: a meta-analysis. Laryngoscope. 2012;122:1974-8.